Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Rakuten Aspyrian Raises $150m VC Round For Laser-Activated Cancer Drugs

Executive Summary

Private investors, including Japanese e-commerce mogul Hiroshi Mikitani, backed a $150m Series C round for Rakuten Aspyrian and its photoimmunotherapy platform. Also, pharma-backed therapeutic video game developer Akili boosts Series C to $68m, and Summit garners additional BARDA funding.

Advertisement

Related Content

Top Financings: 2018 Was A Remarkable Year For Biopharma Fundraising
Finance Watch: Former Juno Execs Launch Sana With Allogeneic Cell Therapy Platform
Finance Watch: Lots Of Money, Big And Small, Flowing Into Drug Development
Beyond DMD, Summit Aims For Top With Novel Antibiotics
Finance Watch: Rhythm And OptiNose IPOs Bring 2017 Total To 31, Surpassing 2016
Finance Watch VC Edition: Biopharma Venture Investment Rises In Second Quarter
Venture Funding Deals: Stem Cell Venture BlueRock Launches With Major Funding
Gilead's Late-Stage R&D Misfire Gives Respite To Competing Myelofibrosis Therapies
Finance Roundup: Tizona, Aspyrian Raise VC Cash; Two Biotechs Ready IPOs
Gilead JAKs up oncology presence with $510m YM buy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123744

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel